Genetic variation in interleukin 28B rs8099917 and response to antiviral therapy in Moroccan patients with chronic hepatitis C

Abstract Background Several studies have shown that the genetic host factors may affect the progression of hepatitis C (HCV) and has an effect on single nucleotide polymorphisms interleukin 28B (IL28B) gene in patients with based treatment of INF/RIB. Objectives The aim of our study is to evaluate the rate of rs8099917 genotypes of IL28B and examine its impact on the responsive treatment among Moroccan patients with chronic Hepatitis C. Patients and methods A total of 173 HCV-positive people who received PEG-IFN/RBV were recruited in this study in which IL28B polymorphisms were genotyped by sequencing. Results the SVR rates of our study were 40% in patients with genotype 1 and 81% in those with genotype 2. The frequencies of the genotypes rs8099917 were 67.05% TT; 31.79% TG and 1.15% GG. Conclusion In the patients with chronic HCV-genotype 1b and 2 infections, IL28B is significantly associated with the responsive treatment of PEG-interferon/ribavirin among Moroccan patients with chronic HCV infection.